Wittenberg Investment Management Inc. Lowers Stock Holdings in Lifecore Biomedical, Inc. (NASDAQ:LFCR)

Wittenberg Investment Management Inc. cut its holdings in shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR - Free Report) by 80.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 11,223 shares of the company's stock after selling 46,673 shares during the quarter. Wittenberg Investment Management Inc.'s holdings in Lifecore Biomedical were worth $83,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. ARS Investment Partners LLC bought a new stake in Lifecore Biomedical during the fourth quarter valued at $74,000. Prudential Financial Inc. bought a new stake in shares of Lifecore Biomedical during the 4th quarter valued at about $95,000. Public Employees Retirement System of Ohio purchased a new position in shares of Lifecore Biomedical during the third quarter worth about $119,000. Barclays PLC raised its stake in Lifecore Biomedical by 301.7% in the third quarter. Barclays PLC now owns 29,944 shares of the company's stock valued at $147,000 after purchasing an additional 22,489 shares in the last quarter. Finally, Lepercq Multi Asset Fund bought a new stake in Lifecore Biomedical during the fourth quarter valued at approximately $169,000. 83.36% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Stephens restated an "equal weight" rating and set a $6.00 price target on shares of Lifecore Biomedical in a research report on Friday, January 3rd.

Lifecore Biomedical Trading Up 11.6 %

Lifecore Biomedical stock traded up $0.60 during trading hours on Wednesday, reaching $5.81. The company had a trading volume of 362,184 shares, compared to its average volume of 223,489. The firm has a market cap of $215.19 million, a price-to-earnings ratio of -10.49 and a beta of 0.80. Lifecore Biomedical, Inc. has a 12-month low of $3.68 and a 12-month high of $7.99. The company has a debt-to-equity ratio of 9.21, a current ratio of 2.32 and a quick ratio of 1.21. The company has a 50-day moving average price of $6.12 and a 200 day moving average price of $6.25.

Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) last released its quarterly earnings data on Thursday, April 3rd. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.05). The firm had revenue of $35.15 million during the quarter, compared to analysts' expectations of $33.23 million. Lifecore Biomedical had a negative net margin of 12.52% and a negative return on equity of 315.23%. Equities analysts forecast that Lifecore Biomedical, Inc. will post -0.91 earnings per share for the current year.

Lifecore Biomedical Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.